Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772382 · ClinicalTrials.gov registry record · Phase 3
Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
A Phase 3 study, sponsored by Tanabe Pharma Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT00772382 is a Phase 3 study that has completed, run by Tanabe Pharma Corporation. The registered enrollment target is 116 participants.
The verdict
NCT00772382, a Phase 3 study, has completed, sponsored by Tanabe Pharma Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia. The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.
Interventions
- DRUG MCI-196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772382
The ClinicalTrials.gov registry entry for NCT00772382 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma Corporation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MCI-196 is the first listed.
NCT00772382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772382 about?
NCT00772382 is a clinical study titled "Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia". The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia. The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.
What is the current status of trial NCT00772382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2008-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00772382?
The interventions under investigation include: MCI-196 (DRUG).
Who is sponsoring clinical trial NCT00772382?
This trial is sponsored by Tanabe Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.